Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae

被引:26
|
作者
Guo, Yingyi [1 ]
Liu, Ningjing [1 ]
Lin, Zhiwei [2 ]
Ba, Xiaoliang [3 ]
Zhuo, Chuyue [1 ]
Li, Feifeng [1 ]
Wang, Jiong [1 ]
Li, Yitan [2 ]
Yao, Likang [1 ]
Liu, Baomo [1 ]
Xiao, Shunian [1 ]
Jiang, Ying [1 ]
Zhuo, Chao [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[2] Peoples Hosp Yangjiang, Lab Resp Dis, Yangjiang, Guangdong, Peoples R China
[3] Univ Cambridge, Dept Vet Med, Cambridge, England
基金
中国国家自然科学基金;
关键词
Ceftazidime-avibactam; KPC; LamB; PBP3; expression level of bla (KPC); IN-VITRO ACTIVITY; ESCHERICHIA-COLI; MOLECULAR EPIDEMIOLOGY; ENTEROBACTERIACEAE; ACID;
D O I
10.1080/22221751.2021.1984182
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ceftazidime-avibactam (CAZ-AVI) shows promising activity against carbapenem-resistant Klebsiella pneumoniae (CRKP), however, CAZ-AVI resistance have emerged recently. Mutations in KPCs, porins OmpK35 and/or OmpK36, and PBPs are known to contribute to the resistance to CAZ-AVI in CRKP. To identify novel CAZ-AVI resistance mechanism, we generated 10 CAZ-AVI-resistant strains from 14 CAZ-AVI susceptible KPC-producing K. pneumoniae (KPC-Kp) strains through in vitro multipassage resistance selection using low concentrations of CAZ-AVI. Comparative genomic analysis for the original and derived mutants identified CAZ-AVI resistance-associated mutations in KPCs, PBP3 (encoded by ftsI), and LamB, an outer membrane maltoporin. CAZ-AVI susceptible KPC-Kp strains became resistant when complemented with mutated bla (KPC) genes. Complementation experiments also showed that a plasmid borne copy of wild-type lamB or ftsI gene reduced the MIC value of CAZ-AVI in the induced resistant strains. In addition, bla (KPC) expression level increased in four of the six CAZ-AVI-resistant strains without KPC mutations, indicating a probable association between increased bla (KPC) expression and increased resistance in these strains. In conclusion, we here identified a novel mechanism of CAZ-AVI resistance associated with mutations in porin LamB in KPC-Kp.
引用
收藏
页码:2042 / 2051
页数:10
相关论文
共 50 条
  • [21] Looking beyond ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae: in vitro activity of the novel meropenem-vaborbactam in combination with the old fosfomycin
    Matteo, Boattini
    Gabriele, Bianco
    Iannaccone, Marco
    Bondi, Alessandro
    Cavallo, Rossana
    Cristina, Costa
    JOURNAL OF CHEMOTHERAPY, 2021, 33 (08) : 598 - 600
  • [22] Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae
    Huang, Yanqin
    Sokolowski, Karol
    Rana, Amisha
    Singh, Nidhi
    Wang, Jiping
    Chen, Ke
    Lang, Yinzhi
    Zhou, Jieqiang
    Kadiyala, Neera
    Krapp, Fiorella
    Ozer, Egon A.
    Hauser, Alan R.
    Li, Jian
    Bulitta, Jurgen B.
    Bulman, Zackery P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (09)
  • [23] In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment
    Gaibani, Paolo
    Campoli, Caterina
    Lewis, Russell E.
    Volpe, Silvia Lidia
    Scaltriti, Erika
    Giannella, Maddalena
    Pongolini, Stefano
    Berlingeri, Andrea
    Cristini, Francesco
    Bartoletti, Michele
    Tedeschi, Sara
    Ambretti, Simone
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (06) : 1525 - 1529
  • [24] Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?
    Corcione, Silvia
    De Benedetto, Ilaria
    Shbaklo, Nour
    Torsello, Giulia
    Lupia, Tommaso
    Bianco, Gabriele
    Cavallo, Rossana
    Brazzi, Luca
    Montrucchio, Giorgia
    De Rosa, Francesco Giuseppe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [25] In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam
    Lombardo, Donatella
    Ambretti, Simone
    Lazzarotto, Tiziana
    Gaibani, Paolo
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (05) : 749 - 751
  • [27] Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-Producing Klebsiella pneumoniae Under Antibiotic Selection Pressure
    Jiang, Min
    Sun, Bin
    Huang, Yong
    Liu, Chengyang
    Wang, Yan
    Ren, Yanli
    Zhang, Yuhong
    Wang, Yunying
    Mu, Di
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 4627 - 4636
  • [28] Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections
    Abichabki, N.
    Gaspar, G. G.
    Bortolato, L. R.
    Lima, D. A. F. S.
    Silva, L. N.
    Pocente, R. H. C.
    Ferreira, J. C.
    Ogasawara, T. C.
    Pereira, D.
    Guerra, R. R.
    Wilhelm, C.
    Barth, P.
    Martins, A. F.
    Barth, A.
    Braga, G. U. L.
    De Martinis, E. C. P.
    Bengtsson-Palme, J.
    Bellissimo-Rodrigues, F.
    Bollela, V. R.
    Darini, A. L. C.
    Andrade, L. N.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2025, 44 (02) : 343 - 353
  • [29] Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae
    Davido, Benjamin
    Cremieux, Anne-Claude
    Vaugier, Isabelle
    Gatin, Laure
    Noussair, Latifa
    Massias, Laurent
    Laurent, Frederic
    Saleh-Mghir, Azzam
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (01)
  • [30] In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae
    Gaibani, Paolo
    Ambretti, Simone
    Viale, PierLuigi
    Re, Maria Carla
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (05) : 1457 - 1459